CEO John Sheridan stated, "2025 was a defining year for Tandem, where we surpassed the milestone of $1 billion in sales while delivering on our mission to provide new innovations, improved outcomes ...
I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness/fitness myths. In my free time I enjoy ...
Investing.com - Mizuho raised its price target on Tandem Diabetes Care (NASDAQ:TNDM) to $22 from $21 while maintaining a Neutral rating on Thursday. The stock currently trades at $18.52, having surged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results